Earnings Summary

Exagen Inc’s revenue jumped 7.23% since last year same period to $13.77Mn in the Q4 2023. On a quarterly growth basis, Exagen Inc has generated 2.6% jump in its revenue since last 3-months.

Exagen Inc’s net profit jumped 61.17% since last year same period to $-5.57Mn in the Q4 2023. On a quarterly growth basis, Exagen Inc has generated -2.92% fall in its net profits since last 3-months.

Exagen Inc’s net profit margin jumped 63.79% since last year same period to -40.49% in the Q4 2023. On a quarterly growth basis, Exagen Inc has generated -0.31% fall in its net profit margins since last 3-months.

Exagen Inc’s earning per share (EPS) estimates for the current quarter stand at -0.36 - a 16.28% jump from last quarter’s estimates.

Exagen Inc’s earning per share (EPS) estimates for the current year stand at -0.36.

Exagen Inc’s earning per share (EPS) jumped 62.65% since last year same period to -0.31 in the Q4 2023. This indicates that the Exagen Inc has generated 62.65% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Exagen Inc’s return on assets (ROA) stands at -0.2.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Exagen Inc’s return on equity (ROE) stands at -0.73.